In this regard, the ARCADIA trial, which aims to compare an anticoagulant strategy with apixaban vs. aspirin in patients with cerebral infarction of undetermined etiology with recognized markers of atrial cardiopathy (P-wave terminal force > 5,000 μV.ms in V1, serum NT-pro-BNP > 250 pg/mL, or left atrial diameter index ≥ 3 cm/m2) (31) should add significant knowledge to this clinical issue. The gene discussed is NPPB; the disease is brain infarction.